All About TAZORAC®

Think acne. Think TAZORAC®. Think results.

When you’ve decided to give acne the boot, you want it clear in your head what works. And why.

Over 4 million prescriptions have been filled for TAZORAC® (tazarotene) Cream or Gel 0.1%.1 Guess why? Because it works!


Test your Acne IQ

TAZORAC® is a retinoid, a type of prescription drug you spread on your skin. The prescription part is important—that means you can’t just grab it off a shelf. You have to see a doctor and get a prescription, take it to a drugstore, take home TAZORAC® Cream or Gel 0.1% and use it exactly like the doc or druggist tells you. Yeah, that’s a bit of effort. But the effort is worth it.

Unlike over-the-counter products, TAZORAC® Cream and Gel 0.1% are FDA prescriptions.

What makes TAZORAC® Cream and Gel 0.1% unique

TAZORAC® Cream and Gel are unique because they are prodrugs. A prodrug is a medication that's supplied in a chemically inactive form and becomes active only after it enters the body.2 In the case of TAZORAC®, the active ingredient (tazarotene) becomes effective medicine (tazarotenic acid) once it passes through the skin.2 No other retinoid behaves the same way.

TAZORAC® is clinically shown to have effective acne-fighting power3-6.

How TAZORAC® Cream or Gel 0.1% works

TAZORAC® Cream or Gel 0.1% starts working fast, right after it soaks in. You can see improvement in as early as 4 weeks. Although you might be one of the large bunch that sees some redness, that's very common when treating acne with a retinoid because your skin is regenerating. Other reactions include peeling, burning, dry skin, or itching.

But you know what? That should pass. If you stick with TAZORAC® Cream or Gel 0.1% for the entire 12-week treatment plan, your skin is going to look better. A lot better.

So, as the expression goes, plan for the best with TAZORAC®. Even if you think it's worse, that just means the medicine is working.

What kind of acne does TAZORAC® Cream and Gel 0.1% treat?

Think ahead

  • Your skin should start to improve after 4 weeks
    • Keep in mind that during the first few weeks of treatment with TAZORAC® Cream or Gel 0.1%, even when the medicine is working, it may appear that your skin is getting worse
    • You may experience peeling, burning, dry skin, redness, or itching
    • This is very common, so don't give up treatment if these side effects occur
  • Be a patient patient
    • Stick with the treatment for the entire 12 weeks as directed by your doctor.
      Studies with TAZORAC® Cream and Gel 0.1% show good results on most people at that point. Give the medicine time to work
    • Always, always, always apply moisturizer before using TAZORAC® Cream or Gel 0.1% to minimize drying and irritation by restoring the skin’s protective barrier.
    • Always use a sunscreen (minimum SPF 15) during treatment to avoid sunburn; because of heightened burning susceptibility when using retinoids such as TAZORAC®, exposure to sunlight (including sunlamps) should be avoided
  • If you have any concerns during your treatment with TAZORAC®, contact your doctor

Think TAZORAC®

TAZORAC® is available in 2 formulations:

  • Nongreasy, easy-to-use cream
  • Cooling, fast-drying gel
  • Your doctor can help you by selecting the type of treatment that is best for you
img img img
 

TAZORAC® (tazarotene) Cream 0.1% is indicated for acne vulgaris.
TAZORAC® (tazarotene) Gel 0.1% is indicated for mild to moderate facial acne vulgaris.

Important Safety Information

Warnings

Retinoids may cause fetal harm when administered to a pregnant woman. Do not use TAZORAC® Cream and Gel if you are pregnant, attempting to become pregnant or at high risk of pregnancy. Consult your physician for adequate birth control measures if you are a female of child-bearing potential. To help assure that you are not pregnant when you begin use, take a pregnancy test within 2 weeks prior to beginning to use TAZORAC® Cream or Gel and/or begin taking TAZORAC® Cream or Gel during a normal menstrual period.

TAZORAC® Cream and Gel should not be used if you are allergic to any of its ingredients. Please see complete Information for Patients for a list of ingredients.

Precautions

TAZORAC® Cream and Gel should not be used if you are also taking other drugs that increase your sensitivity to sunlight (e.g., thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides). Inform your physician if you are taking any other medications. Use protective clothing and sunscreens of at least SPF 15 during the day when using TAZORAC® Cream and Gel. Do not use TAZORAC® Cream and Gel if you have sunburn, eczema, or other continuing skin condition. Use TAZORAC® Cream and Gel with caution if you are using other topical products that might dry or irritate the skin.

The most common side effects of TAZORAC® Cream and Gel 0.1% are peeling, burning/stinging, dry skin, red skin, and itching.

Please click here for full prescribing information for TAZORAC® Cream and Gel 0.1%.

 
img img img

  1. Verispan, LLC. Vector One: National (VONA). Yardley, PA; Verispan LLC; July 1997 - December 2006.
  2. TAZORAC® Prescribing information.
  3. Shalita A, Miller B, Menter A, Abramovits W, Loven K, Kakita L. Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized parallel-group study. J Drugs Dermatol. 2005;4(2):153-158.
  4. Webster GF, Guenther L, Poulin YP, Solomon BA, Loven K, Lee J. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis. 2002;69(suppl 2):4-11.
  5. Leyden JJ, Tanghetti EA, Miller B, Ling M, Berson D, Lee J. Once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.1% microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Cutis. 2002;69(suppl 2):12-19.
  6. Webster GF, Berson D, Stein LF, Fivenson DP, Tanghetti EA, Ling M. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis. 2001;67(suppl 6):4-9.

Allergan Dermatology
©2008 Allergan, Inc., Irvine, CA 92612. ® marks owned by Allergan, Inc.